Investment Objective
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM).
The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.
Latest FBT News
Performance
| 1 month | -5.11% | | 3 years | +19.93% |
| 3 months | +5.81% | | 5 years | +19.81% |
| 1 year | +30.50% | | Since inception | +16.23% |
Quote Details
| Previous close | $56.53 |
| Open day’s range | 56.40 – 57.43 |
| Net asset value (NAV) | 56.60 (06/17/2013) |
| Daily volume | 24,375 |
| Average volume (3 months) | 56,047 |
Data as of 3:59pm ET, 06/18/2013
Peer Comparisonvs. Health ETFs
| | FBT | Category |
|---|
| Performance 5-yr return | +19.81% | +13.03% |
| Expense Gross exp ratio | 0.61% | 0.47% |
| Risk 5 year sharpe ratio | 0.80 | 0.76 |
| Net assets | $347.9M | $762.0M |
| Average market cap | $5.6B | $19.5B |
| Average P/E | 27.3 | 21.7 |
| Dividend / Share | -- | 0.22% |
Competitors
| VHT Vanguard Health Care ETF |
| XLV Health Care Select Sector SPDR Fund |
| IXJ iShares S&P Global Healthcare Index Fund |
Holdings
Top 5 Sectors
Portfolio weighting
Top 10 Holdings
Portfolio weighting
| ILMN Illumina, Inc. | 5.73% |
| UTHR United Therapeutics Corporation | 5.51% |
| BIIB Biogen Idec Inc | 5.35% |
| IMGN Immunogen, Inc. | 5.31% |
| ALXN Alexion Pharmaceuticals, Inc. | 5.26% |
| DNDN Dendreon Corp | 5.12% |
| INCY Incyte Corp Ltd | 5.07% |
| ITMN InterMune, Inc. | 5.03% |
| REGN Regeneron Pharmaceuticals, Inc. | 5.03% |
| BMRN Biomarin Pharmaceutical, Inc. | 4.98% |
+0.68 / +1.20%
-0.48 / -0.84%
.
